文献速递血栓与止血

癌症患者临床相关出血:全国性队列研究启示

Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study.
PubMed 文献 · Am J Hematol · 2026-06-03

该研究利用Epic Cosmos数据库纳入2018至2024年间美国215个卫生系统2 455 332例新发癌症患者,评估癌症相关临床相关出血(CRB)的影响。癌症诊断前12个月CRB期间患病率为5.3%,诊断后12个月累积发生率为6.3%,接受全身抗肿瘤治疗者为7.0%,某些基线抗凝治疗者高达15.0%。CRB发生与死亡率独立相关,颅内出血HR 4.17(95%CI 4.11-4.24),胃肠道出血HR 2.52(95%CI 2.50-2.55),其他出血HR 2.46(95%CI 2.44-2.49)。

要点

  • 癌症诊断前12个月CRB期间患病率5.3%,提示出血可为癌症早期表现。
  • 诊断后12个月CRB累积发生率6.3%,全身治疗者7.0%,某些基线抗凝者达15.0%。
  • CRB发生与死亡率独立相关,颅内出血HR 4.17,胃肠道出血HR 2.52。

核心结论

  • 癌症患者临床相关出血风险显著且被低估,与死亡率独立相关,需整合出血风险模型以指导个体化血栓预防决策。

研究设计与样本

  • 基于Epic Cosmos数据库的全国性队列研究,纳入2018至2024年美国215个卫生系统2 455 332例新发癌症就诊个体。

主要发现

  • 癌症诊断前12个月CRB期间患病率为5.3%。
  • 癌症诊断后12个月CRB累积发生率总体为6.3%,接受全身抗肿瘤治疗者为7.0%,某些基线抗凝治疗者高达15.0%。
  • 多变量分析中与CRB显著相关的因素包括年龄、性别、种族、癌症类型、转移性疾病、全身治疗、抗凝或抗血小板使用、较高合并症指数、近期住院、近期出血或VTE史及选择性实验室指标(血红蛋白、血小板、白蛋白、eGFR)。
  • CRB作为时变协变量与死亡率独立相关:颅内出血HR 4.17(95%CI 4.11-4.24);胃肠道出血HR 2.52(95%CI 2.50-2.55);其他出血HR 2.46(95%CI 2.44-2.49)。

临床怎么用

  • 临床应关注癌症患者出血风险,尤其在接受全身抗肿瘤治疗或基线抗凝治疗者中。
  • 需开发并验证可整合至VTE预测工具的出血风险模型,以指导个性化血栓预防决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer care is often complicated by coagulopathy leading to thrombosis and bleeding. While venous thromboembolism (VTE) has been extensively studied, bleeding remains an underestimated threat. To address this knowledge gap, we leveraged the Epic Cosmos database to determine the impact of cancer-associated clinically relevant bleeding (CRB) in 2 455 332 individuals with incident cancer encounters from 215 US health systems between 2018 and 2024. In the 12 months leading up to the cancer diagnosis, the period prevalence of CRB was 5.3% in the overall cohort, highlighting CRB as a common early presentation preceding cancer diagnosis. In the 12-month window after cancer diagnosis, the cumulative incidence of CRB was 6.3% in the overall cohort, 7.0% in those receiving systemic antineoplastic therapy, and up to 15.0% among individuals on certain baseline anticoagulants. In addition to age, sex, and race, factors appreciably associated with CRB on multivariable analysis included cancer types, metastatic disease, systemic therapy, anticoagulant or antiplatelet use, higher comorbidity index, recent hospitalization, recent history of bleeding or VTE, and selective laboratory features (hemoglobin, platelets, albumin, eGFR). Furthermore, the onset of CRB as a time varying covariate was independently associated with mortality in multivariable adjusted analysis: intracranial hemorrhage (HR 4.17, 95% CI 4.11-4.24); gastrointestinal bleeding (HR 2.52, 95% CI 2.50-2.55); other bleeding (HR 2.46, 95% CI 2.44-2.49). Together, these findings reveal a substantial and overlooked risk of bleeding in cancer care and underscore a need for validated bleeding risk models that can be integrated alongside VTE prediction tools to guide personalized thromboprophylaxis decisions.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lim MY, Gangaraju R, Jafari O, et al. Clinically Relevant Bleeding in Individuals With Cancer: Insights From a Nationwide Cohort Study. Am J Hematol. 2026. PMID: 42237094. doi:10.1002/ajh.70394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。